2242751-53-5
2242751-53-5
Chemical Structure
Acoramidis hydrochloride
Synonym(s): AG10 hydrochloride
- CAS 番号: 2242751-53-5
- Formula:C15H18ClFN2O3
- Molecular Weight:328.77
IUPAC Name: 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid hydrochloride
InChIKey: MGFZEARHINUOMX-UHFFFAOYSA-N
SMILES: O=C(O)C1=CC=C(F)C(OCCCC2=C(C)NN=C2C)=C1.[H]Cl
Biological Activity: Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis[1][2].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acoramidis hydrochloride | 98.47% | Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acoramidis hydrochloride (Standard) | ≥98% | Acoramidis hydrochloride (Standard) is the analytical standard of Acoramidis (hydrochloride) (HY-109165A). This product is intended for research and analytical applications. Acoramidis (AG10) hydrochloride is an orally active and selective Kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sravan C Penchala, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9992-7. [Content Brief]
- [2]. Jonathan C Fox, et al. First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers. Clin Pharmacol Drug Dev. 2020 Jan;9(1):115-129. [Content Brief]
